Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization.

ABSTRACT:

Background

Dual antiplatelet therapy (DAPT) after coronary stenting prolongs survival by preventing both in-stent thrombosis and other cardiovascular atherothrombotic events. Patients with peripheral artery disease (PAD) typically have a heavy burden of unrevascularized coronary artery disease and also stand to benefit from increased atherothrombotic protection with DAPT. The potential benefit of DAPT compared with aspirin alone in patients with PAD is not well described.

Methods

We identified all patients undergoing an initial elective lower extremity revascularization (bypass or endovascular) from 2003 to 2016 in the Vascular Quality Initiative registry discharged on aspirin or aspirin plus a thienopyridine antiplatelet agent (DAPT). We first estimated models predicting th

SUBMITTER: Soden PA 

PROVIDER: S-EPMC5121016 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature